Ipamorelin Dosage & Results: An Honest Guide

“Ipamorelin dosage” searches almost always come bundled with “results” — people want a number to inject and a timeline of what they'll see. This guide gives you the doses that circulate in clinic and research-community protocols, but it does so with a hard line drawn through the middle: the dose is research convention, and most of the “results” you'll read about are anecdotal, not trial-proven. Ipamorelin is a growth-hormone secretagogue. It is not an FDA-approved drug, there is no approved dose, and what it has actually been shown to do in controlled human studies is narrower than the before-and-after photos suggest.

What ipamorelin is, and why dosing is even possible to discuss

Ipamorelin is a synthetic pentapeptide that acts on the ghrelin receptor (the GH-secretagogue receptor) to trigger a pulse of your own growth hormone (GH). Its claim to fame, established in the original animal characterization, is selectivity: it releases GH without the spikes in cortisol and prolactin that older GH-releasing peptides like GHRP-6 and GHRP-2 cause¹. That clean profile is the real reason it became the community-favorite GHRP. But “selective and clean” describes the mechanism — it does not by itself prove a body-composition payoff. (For how that clean profile compares to GHRH peptides, see sermorelin vs ipamorelin.)

Because ipamorelin is short-acting — a brief GH pulse that clears within roughly a couple of hours — dosing protocols are built around hitting that pulse at useful times, not around a long-lasting drug level.

The doses that actually circulate

There is no FDA label, so every number below is clinic-protocol or research convention, not validated dosing. With that stated plainly:

The most commonly cited protocol is a fixed ~100–300 mcg per injection, given one to three times daily by subcutaneous injection, on an empty stomach (food — especially fat and carbohydrate — blunts the GH pulse). The single most common timing is at bedtime, to reinforce the body's largest natural GH pulse, which occurs in early deep sleep. A second dose is often placed in the morning or post-workout. Many protocols pair ipamorelin with a GHRH analog such as CJC-1295, because the two receptors act synergistically — a GHRP given with GHRH produces a larger GH pulse than either alone². (We cover that combination in the sermorelin + ipamorelin stack, and the partner peptide's schedule in CJC-1295 dosing.)

One genuine human-trial anchor for dosing exists, though not for the use people buy ipamorelin for: a randomized, placebo-controlled trial gave ipamorelin to patients recovering from bowel surgery to treat postoperative ileus³. That trial used the peptide as an investigational gut-motility agent — it tells you ipamorelin can be dosed in humans under study conditions, not that any wellness dose produces muscle or fat-loss results.

“Results”: what's real, what's anecdotal

This is the part the marketing inflates most. Here is the honest breakdown.

What is genuinely documented: ipamorelin raises growth hormone with a favorable selectivity profile (little cortisol/prolactin) compared with other secretagogues¹, and GHRP-class peptides reliably stimulate GH release in humans, including with chronic dosing⁴. That is a biochemical result — a measurable GH and (over time) IGF-1 elevation.

What is largely anecdotal or clinic-marketed: the timeline of visible results — “better sleep in the first week,” “fat loss by week four,” “lean-muscle gains by week twelve.” These come from user reports, clinic testimonials, and inference from GH physiology, not from controlled body-composition trials of ipamorelin. No modern randomized trial has shown ipamorelin changes muscle mass, body fat, strength, or appearance in healthy adults. So any results timeline — including the one in the figure below — should be read as what the GH response and user reports suggest you might notice, with the strength of evidence falling sharply the further out you go.

Why your results may be smaller than the charts promise

A dose does not buy a fixed amount of growth hormone. GH output is capped by somatostatin and declines markedly with age and with greater visceral fat — older and heavier adults release substantially less GH to the same stimulus⁵. That is the exact demographic most likely to be chasing these peptides, and it means an identical protocol can produce a much smaller hormonal response — and smaller “results” — in the people most hoping for them. Eating before a dose, dosing at the wrong time, or carrying excess visceral fat all blunt the response further. The lever that matters is not pushing the microgram count up (which mostly raises side-effect risk — water retention, head-rush, hunger, tingling, elevated IGF-1); it's whether your physiology can mount a GH pulse at all. (For the full safety picture, see ipamorelin side effects.)

The honest bottom line

Ipamorelin's dosing is research convention, not FDA guidance: roughly 100–300 mcg subcutaneously, one to three times daily, empty-stomach, usually bedtime, often stacked with a GHRH analog. What it's actually proven to do is raise GH cleanly¹ — a biochemical result. The body-composition “results” that sell it are largely anecdotal, with no modern outcome trial behind them, and they shrink in exactly the older, heavier people most likely to want them⁵. If you're considering it, treat the dose as the least consequential decision and the source quality, lack of approval, and IGF-1/glucose monitoring as the real ones. For the broader evidence picture, start with our pillar guide to sermorelin and GH-axis evidence and, if you want to see how the clinics offering these peptides compare, our guide to the best sermorelin providers.